Silverback Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $2,068 | $500 | $0 | $-30 |
Gross Profit | 1,956 | 482 | -11 | -42 |
EBITDA | -21,748 | -15,322 | -13,181 | -10,214 |
EBIT | -15,340 | -13,192 | -10,226 | |
Net Income | -19,128 | -12,516 | -10,292 | -7,168 |
Net Change In Cash | 2,068 | 500 | 0 | -30 |
Free Cash Flow | -14,607 | -7,317 | -6,793 | -17,314 |
Cash | 39,657 | 36,626 | 56,006 | 70,971 |
Basic Shares | 97,032 | 96,827 | 96,486 | 96,414 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $30 | $1,316 | $5,506 | $17,835 |
Gross Profit | -43 | -16,004 | -14,767 | 3,765 |
EBITDA | -67,447 | -35,516 | -19,241 | -463 |
EBIT | -67,520 | -35,835 | -19,454 | -2,173 |
Net Income | -54,365 | -33,988 | -20,243 | -1,065 |
Net Change In Cash | 30 | 1,316 | 5,506 | 17,835 |
Cost of Revenue | 150,455 | |||
Free Cash Flow | -59,441 | -40,277 | -17,616 | 8,154 |
Cash | 70,971 | 210,518 | 60,063 | 24,521 |
Basic Shares | 95,215 | 39,956 | 28,872 | 34,701 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.20 |
2024-06-30 | -$0.13 |
2024-03-31 | -$0.11 |
2023-12-31 | -$0.07 |
